**Appendices**

**Appendix 3****: Data extraction**

The following information, where available, was extracted from the included publications into pre-specified data extraction tables.

* Author, publication details, abstract
* Study country/countries
* Year study enrolment started
* Cancer type (broad category and whether solid or hematological malignancy)
* Intervention name and whether cancer treatment or supportive care
* Total sample size
* Enrollee age (median, range or mean, SD)
* Male, Female (n, %)
* US race/ethnicity categories (n, %): White/Caucasian, Black/African American, Asian, Hawaiian/Pacific Islander, American Indian/Alaskan, >1 Race, Other Race, Hispanic/Latino
* Gender-specific malignancy? (Yes/No)
* Clinical trial region: whether the population was US only, ex-US only (1 or more countries, excluding the US), or mixed US/ex-US (the US and 1 or more country) (Yes/No/not reported [unable to ascertain])
* Race/ethnicity reported? (Yes/No); for studies conducted in Asian countries (eg, Japan, South Korea, China, Vietnam), the population was classified as 100% Asian and race/ethnicity reported was coded as “yes”
* First in humans? (Yes/No/not reported [unable to ascertain])
* Healthy volunteers? (Yes/No)

**Classification of region**

Clinical trials were categorized into 3 regions: conducted in the US only, outside of the US only, or mixed US and other countries. An additional category of “not reported” was also included if region could not be ascertained. Regions were defined as follows:

* Where country of the trial was reported in the publication or supplemental materials, this information was used to identify region.
* If country was not specified, clinical author affiliation and institutional review board, where available, were used to identify the region.
* Where it was not clear from author affiliation or institutional review board location, if this information was contradictory or missing, or if there was evidence in the ClinicalTrials.gov record that some countries were removed, the region was classified as not reported.

**Appendix 4: Included Publications**

1. Abdul Razak AR, Miller WH, Uy GL, et al. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. *Invest New Drugs.* 2019;doi:10.1007/s10637-020-00907-4.

2. Abramson VG, Oliveira M, Cervantes A, et al. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. *Breast Cancer Res Treat.* 2019;178(1):121-133.

3. Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. *JAMA Oncol.* 2019;5(3):334-342.

4. Ando Y, Iwasa S, Takahashi S, et al. Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. *Cancer Sci.* 2019;110(3):1021-1031.

5. Andritsos LA, Byrd JC, Cheverton P, et al. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. *Leuk Lymphoma.* 2019;60(14):3461-3469.

6. Annels NE, Mansfield D, Arif M, et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. *Clin Cancer Res.* 2019;25(19):5818-5831.

7. Appleman LJ, Beumer JH, Jiang Y, et al. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. *Cancer Chemother Pharmacol.* 2019;84(6):1289-1301.

8. Argiles G, Andre T, Hollebecque A, et al. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. *Eur J Cancer.* 2019;112:12-19.

9. Atrafi F, Groen HJM, Byers LA, et al. A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors. *Clin Cancer Res.* 2019;25(2):496-505.

10. Azmi AS, Khan HY, Muqbil I, et al. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. *Clin Cancer Res.* 2019;12:12.

11. Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. *Lancet Oncol.* 2019;20(8):1160-1170.

12. Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. *Clin Cancer Res.* 2019;25(16):4888-4897.

13. Baird RD, van Rossum AGJ, Oliveira M, et al. POSEIDON trial phase 1B results: safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients. *Clin Cancer Res.* 2019;25(22):6598-6605.

14. Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol.* 2019;20(8):1124-1135.

15. Bang YJ, Su WC, Schuler M, et al. Phase I study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. *Cancer Sci.* 2019;28:28.

16. Bardia A, Gounder M, Rodon J, et al. Phase Ib study of combination therapy with MEK inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS/RAF alterations. *Oncologist.* 2020;25(1):e160-e169.

17. Bauer TM, Besse B, Martinez-Marti A, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. *J Thorac Oncol.* 2019;14(10):1828-1838.

18. Baumeister SH, Murad J, Werner L, et al. Phase i trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. *Cancer Immunology Research.* 2019;7(1):100-112.

19. Bekaii-Saab T, Wesolowski R, Ahn DH, et al. Phase i immunotherapy trial with two chimeric HER-2 B-Cell peptide vaccines emulsified in montanide ISA 720VG and Nor-MDP adjuvant in patients with advanced solid tumors. *Clin Cancer Res.* 2019;25(12):3495-3507.

20. Bendell JC, Bischoff HG, Hwang J, et al. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00873-6.

21. Bendell JC, Patel MR, Moore KN, et al. Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of vorolanib in patients with advanced solid tumors. *Oncologist.* 2019;24(4):455-e121.

22. Bentebibel SE, Hurwitz ME, Bernatchez C, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbetagamma-biased cytokine, in patients with advanced or metastatic solid tumors. *Cancer Discov.* 2019;9(6):711-721.

23. Benton CB, Chien KS, Tefferi A, et al. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. *Hematol Oncol.* 2019;37(1):96-102.

24. Besse B, Barlesi F, Demedts I, et al. A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer. *Lung Cancer.* 2019;137:136-143.

25. Bhatnagar B, Zhao Q, Mims AS, et al. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. *Leuk Lymphoma.* 2019:1-10.

26. Bhatty M, Kato S, Piha-Paul SA, et al. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. *Cancer.* 2019;125(3):463-472.

27. Bian L, Zhang H, Wang T, et al. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. *Ann Transl Med.* 2019;7(18):435.

28. Bilusic M, Heery CR, Collins JM, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. *J Immunother Cancer.* 2019;7(1):240.

29. Blagden SP, Hamilton AL, Mileshkin L, et al. Phase IB dose escalation and expansion study of akt inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer. *Clin Cancer Res.* 2019;25(5):1472-1478.

30. Boll B, Plutschow A, Burkle C, et al. Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial. *Br J Haematol.* 2019;185(1):42-52.

31. Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2019;158(1):269-276.

32. Brierley CK, Staves J, Roberts C, et al. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. *Transfusion.* 2019;59(7):2248-2254.

33. Campone M, Bachelot T, Penault-Llorca F, et al. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. *Cancer Chemother Pharmacol.* 2019;83(4):743-753.

34. Carlo-Stella C, Delarue R, Scarfo L, et al. A first-in-human study of tenalisib (RP6530), a dual PI3K delta/gamma Inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study. *Clin Lymphoma Myeloma Leuk.* 2020;20(2):78-86.

35. Chalmers AW, Patel S, Boucher K, et al. Phase I trial of targeted EGFR or ALK therapy with ipilimumab in metastatic NSCLC with long-term follow-up. *Target Oncol.* 2019;14(4):417-421.

36. Cheung KWK, Yoshida K, Cheeti S, et al. GDC-0810 pharmacokinetics and transporter-mediated drug interaction evaluation with an endogenous biomarker in the first-in-human, dose escalation study. *Drug Metab Dispos.* 2019;47(9):966-973.

37. Chia S, Bedard PL, Hilton J, et al. A phase Ib trial of durvalumab in combination with trastuzumab in HER2-positive metastatic breast cancer (CCTG IND.229). *Oncologist.* 2019;24(11):1439-1445.

38. Chihara Y, Date K, Takemura Y, et al. Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. *Invest New Drugs.* 2019;37(2):291-296.

39. Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. *Sci Transl Med.* 2019;11(505):eaaw5680.

40. Cho SH, Han S, Ghim JL, et al. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. *Biodrugs.* 2019;33(2):173-181.

41. Choueiri TK, Michaelson MD, Posadas EM, et al. An open label phase Ib dose escalation study of TRC105 (anti-endoglin antibody) with axitinib in patients with metastatic renal cell carcinoma. *Oncologist.* 2019;24(2):202-210.

42. Chung HC, Arkenau HT, Lee J, et al. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. *J Immunother Cancer.* 2019;7(1):30.

43. Chung V, Kos FJ, Hardwick N, et al. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. *Clin Transl Oncol.* 2019;21(3):363-372.

44. Clark AS, McAndrew NP, Troxel A, et al. Combination paclitaxel and palbociclib: results of a phase I trial in advanced breast cancer. *Clin Cancer Res.* 2019;25(7):2072-2079.

45. Clarke JM, Blobe GC, Strickler JH, et al. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). *Cancer Chemother Pharmacol.* 2019;84(4):909-917.

46. Clingan PR, Ackland SP, Brungs D, et al. First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment. *Asia Pac J Clin Oncol.* 2019;15(3):151-157.

47. Coffey GP, Feng J, Betz A, et al. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory b-cell malignancies. *Clin Cancer Res.* 2019;25(4):1174-1184.

48. Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J Clin Invest.* 2019;129(6):2210-2221.

49. Cohen EEW, Pishvaian MJ, Shepard DR, et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. *J Immunother Cancer.* 2019;7(1):342.

50. Conlon KC, Lake Potter E, Pittaluga S, et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. *Clin Cancer Res.* 2019;25(16):4945-4954.

51. Cox MC, Castiello L, Mattei M, et al. Clinical and antitumor immune responses in relapsed/refractory follicular lymphoma patients after intranodal injections of IFNalpha-Dendritic cells and rituximab: a phase I clinical trial. *Clin Cancer Res.* 2019;25(17):5231-5241.

52. Crosby EJ, Gwin W, Blackwell K, et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. *Clin Cancer Res.* 2019;25(9):2725-2736.

53. Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. *J Immunother Cancer.* 2019;7(1):175.

54. Danila DC, Szmulewitz RZ, Vaishampayan U, et al. Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer. *J Clin Oncol.* 2019:JCO1900646.

55. Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. *Lancet Haematol.* 2019;6(1):e38-e47.

56. Davis SL, Cardin DB, Shahda S, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. *Invest New Drugs.* 2020;38(3):821-830.

57. de Jonge MJA, Steeghs N, Lolkema MP, et al. Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. *Target Oncol.* 2019;14(1):43-55.

58. de Weger VA, de Jonge M, Langenberg MHG, et al. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. *Br J Cancer.* 2019;120(3):286-293.

59. Di Giacomo AM, Covre A, Finotello F, et al. Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial. *Clin Cancer Res.* 2019;25(24):7351-7362.

60. Dillon MT, Grove L, Newbold KL, et al. Patritumab with cetuximab plus platinum-containing therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: an open-label, phase Ib study. *Clin Cancer Res.* 2019;25(2):487-495.

61. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. *Blood.* 2019;133(1):7-17.

62. Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. *JAMA Oncol.* 2019;5(3):393-401.

63. Dittrich C, Konigsberg R, Mittlbock M, et al. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. *Invest New Drugs.* 2019;37(1):127-138.

64. Doi T, Aramaki T, Yasui H, et al. A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors. *Invest New Drugs.* 2019;37(5):1061-1074.

65. Doi T, Fujiwara Y, Matsubara N, et al. Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2019;84(2):393-404.

66. Doi T, Iwasa S, Muro K, et al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. *Gastric Cancer.* 2019;22(4):817-827.

67. Doi T, Matsubara N, Kawai A, et al. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00859-4.

68. Doi T, Muro K, Ishii H, et al. A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors. *Clin Cancer Res.* 2019;25(22):6614-6622.

69. Doi T, Yang JC, Shitara K, et al. Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors. *Target Oncol.* 2019;14(1):57-65.

70. Doi T, Yoh K, Shitara K, et al. First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. *Invest New Drugs.* 2019;37(3):507-518.

71. Duan JC, Wang ZJ, Lin L, et al. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. *Invest New Drugs.* 2019;37(4):731-737.

72. Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. *Blood Adv.* 2019;3(16):2491-2498.

73. Ebata T, Shimizu T, Fujiwara Y, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. *Invest New Drugs.* 2020;38(2):468-477.

74. Elez E, Gomez-Roca C, Soto Matos-Pita A, et al. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. *Invest New Drugs.* 2019;37(4):674-683.

75. Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. *JAMA Oncol.* 2019;5(1):74-82.

76. Erba HP, Becker PS, Shami PJ, et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. *Blood Adv.* 2019;3(13):1939-1949.

77. Ernani V, Jahan R, Smith LM, et al. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): a Fred and Pamela Buffet Cancer Center Clinical Trials Network study. *Cancer Treatment And Research Communications.* 2019;22:100162.

78. Esaki T, Hirai F, Makiyama A, et al. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. *Cancer Sci.* 2019;110(4):1340-1351.

79. Evans SO, Jacobson GM, Goodman HJB, Bird S, Jameson MB. Comparative safety and pharmacokinetic evaluation of three oral selenium compounds in cancer patients. *Biol Trace Elem Res.* 2019;189(2):395-404.

80. Evans TRJ, Dean E, Molife LR, et al. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. *Br J Cancer.* 2019;120(4):379-386.

81. Even C, Lassen U, Merchan J, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. *Invest New Drugs.* 2020;38:402-409.

82. Eyre TA, Collins GP, Gupta A, et al. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. *Cancer.* 2019;125(1):99-108.

83. Falchook GS, Kurzrock R, Amin HM, et al. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. *Clin Cancer Res.* 2020;26(6):1237-1246.

84. Fan B, Mellinghoff IK, Wen PY, et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. *Invest New Drugs.* 2019;38(2):433-444.

85. Felip E, de Braud FG, Maur M, et al. Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: ceritinib plus nivolumab in ALK-rearranged NSCLC. *J Thorac Oncol.* 2020;15(3):392-403.

86. Fenn K, Maurer M, Lee SM, et al. Phase 1 study of erlotinib and metformin in metastatic triple-negative breast cancer. *Clin Breast Cancer.* 202-;20(1):80-86.

87. Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. *Blood.* 2019;133(26):2765-2775.

88. Fong L, Hotson A, Powderly J, et al. Adenosine A2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. *Cancer Discov.* 2019;15:15.

89. Friedlander M, Meniawy T, Markman B, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. *Lancet Oncol.* 2019;20(9):1306-1315.

90. Froysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. *Eur J Surg Oncol.* 2019;doi:10.1016/j.ejso.2019.04.014.

91. Fujikawa H, Toiyama Y, Inoue Y, et al. Phase I study of preoperative chemoradiotherapy with sequential oxaliplatin and irinotecan with S-1 for locally advanced rectal cancer. *Oncol Lett.* 2019;17(4):3930-3936.

92. Fujiwara Y, Iguchi H, Yamamoto N, et al. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. *Cancer Sci.* 2019;110(5):1715-1723.

93. Gaillard SL, Zahurak M, Sharma A, et al. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. *Cancer.* 2019;125(16):2837-2845.

94. Gan HK, Millward M, Hua Y, et al. First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: Safety, pharmacokinetics, and antitumor activity. *Clin Cancer Res.* 2019;25(16):4924-4932.

95. Gangat N, Marinaccio C, Swords R, et al. Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial. *Clin Cancer Res.* 2019;25(16):4898-4906.

96. Garcia M, Moreno R, Gil-Martin M, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. *Hum Gene Ther.* 2019;30(3):352-364.

97. Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol.* 2019;37(28):2518-2527.

98. Garrido-Laguna I, Krop I, Burris HA, et al. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. *Int J Cancer.* 2019;145(7):1798-1808.

99. Gatti-Mays ME, Redman JM, Donahue RN, et al. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer. *Oncologist.* 2019;doi:10.1634/theoncologist.2019-0608.

100. Gatti-Mays ME, Strauss J, Donahue RN, et al. A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. *Clin Cancer Res.* 2019;25(16):4933-4944.

101. George DJ, Halabi S, Healy P, et al. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. *Prostate.* 2019;79(15):1752-1761.

102. Gerber DE, Infante JR, Gordon MS, et al. Phase Ia study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in non-small cell lung cancer and platinum-resistant ovarian cancer patients. *Clin Cancer Res.* 2020;26(2):364-372.

103. Geyer MB, Riviere I, Senechal B, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. *JCI Insight.* 2019;5(9):e122627.

104. Gibney GT, Hamid O, Lutzky J, et al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. *J Immunother Cancer.* 2019;7(1):80.

105. Gluck WL, Gounder MM, Frank R, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. *Invest New Drugs.* 2020;38(3):831-843.

106. Godfrey JK, Nabhan C, Karrison T, et al. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. *Cancer.* 2019;125(11):1830-1836.

107. Goel S, Swami U, Kumar K, et al. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. *Cancer Chemother Pharmacol.* 2019;84(3):567-578.

108. Goff LW, Azad NS, Stein S, et al. Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. *Invest New Drugs.* 2019;37(2):315-322.

109. Goff SL, Morgan RA, Yang JC, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-Transduced t cells targeting egfrviii in patients with glioblastoma. *J Immunother.* 2019;42(4):126-135.

110. Goffin JR, Nicholas G, Mates M, et al. Canadian Cancer Trials Group (CCTG) IND215: a phase Ib study of selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. *Invest New Drugs.* 2019;37(3):498-506.

111. Gomez-Roca CA, Italiano A, Le Tourneau C, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. *Ann Oncol.* 2019;30(8):1381-1392.

112. Gong J, Cho M, Gupta R, et al. A pilot study of vinorelbine safety and pharmacokinetics in patients with varying degrees of liver dysfunction. *Oncologist.* 2019;24(8):1137-1145.

113. Goodwin R, Jonker D, Chen E, et al. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00814-3.

114. Gordon SW, McGuire WP, Shafer DA, et al. Phase I study of sorafenib and vorinostat in advanced hepatocellular carcinoma. *Am J Clin Oncol.* 2019;42(8):649-654.

115. Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. *Blood.* 2019;134(13):1024-1036.

116. Gray JE, Saltos A, Tanvetyanon T, et al. Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer. *Clin Cancer Res.* 2019;25(22):6623-6632.

117. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. *Blood.* 2019;133(5):436-445.

118. Guan X, Chen S, Yi Z, et al. Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: a phase I clinical trial. *Clin Cancer Res.* 2019;25(17):5212-5220.

119. Guo JX, Wu CX, Wang PF, et al. Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients. *Frontiers in bioscience (Landmark edition).* 2019;24:1158-1166.

120. Haas AR, Tanyi JL, O'Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. *Mol Ther.* 2019;27(11):1919-1929.

121. Hahn AW, Drake C, Denmeade SR, et al. A phase I study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with refractory metastatic renal cell carcinoma. *Oncologist.* 2019;25:121-e213.

122. Hall PE, Lewis R, Syed N, et al. A phase I study of pegylated arginine deiminase (Pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma. *Clin Cancer Res.* 2019;25(9):2708-2716.

123. Hamid O, Molinero L, Bolen CR, et al. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab. *Clin Cancer Res.* 2019;25(20):6061-6072.

124. Harding JJ, Bauer TM, Tan DSW, et al. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. *Invest New Drugs.* 2019;37(2):271-281.

125. Hassan R, Alley E, Kindler H, et al. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma. *Clin Cancer Res.* 2019;25(19):5787-5798.

126. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. *JAMA Oncol.* 2019;5(3):351-357.

127. He AR, Cohen RB, Denlinger CS, et al. First-in-human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer. *Oncologist.* 2019;24(9):e930-e942.

128. Hellmann MD, Kim TW, Lee CB, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. *Ann Oncol.* 2019;30(7):1134-1142.

129. Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. *Lancet Oncol.* 2019;20(8):1109-1123.

130. Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. *Ann Oncol.* 2019;30(2):325-331.

131. Hong DS, LoRusso P, Hamid O, et al. Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. *Clin Cancer Res.* 2019;25(8):2403-2413.

132. Hu XS, Han XH, Yang S, et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. *Cancer Manag Res.* 2019;11:4449-4459.

133. Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. *Cancer.* 2019;125(5):742-749.

134. Huang M, Gong Y, Zhu J, et al. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. *Invest New Drugs.* 2020;38(2):478-484.

135. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. *N Engl J Med.* 2019;381(24):2315-2326.

136. Huijts CM, Werter IM, Lougheed SM, et al. Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. *Cancer Immunol Immunother.* 2019;68(2):319-329.

137. Ikeda M, Morimoto M, Tajimi M, et al. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. *Invest New Drugs.* 2019;37(1):118-126.

138. Ikeda M, Ohno I, Ueno H, et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. *Invest New Drugs.* 2019;37(1):109-117.

139. Irenaeus SMM, Nielsen D, Ellmark P, et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. *Int J Cancer.* 2019;145(5):1189-1199.

140. Jansen YJL, Verset G, Schats K, et al. Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. *ESMO Open.* 2019;4(2):e000464.

141. Jazieh K, Molina J, Allred J, et al. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. *Invest New Drugs.* 2019;37(2):307-314.

142. Jeon JY, Zhao Q, Buelow DR, et al. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positve AML. *Invest New Drugs.* 2020;38(2):340-349.

143. Jimeno A, Moore KN, Gordon M, et al. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. *Invest New Drugs.* 2019;37(3):461-472.

144. Joerger M, Stathis A, Metaxas Y, et al. A phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00850-z.

145. Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors. *Clin Cancer Res.* 2019;25(11):3220-3228.

146. Jung SY, Hwang S, Clarke JM, et al. Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. *Invest New Drugs.* 2020;38(3):812-820.

147. Juric D, Janku F, Rodon J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. *JAMA Oncol.* 2019;5(2):e184475.

148. Kahl BS, Hamadani M, Radford J, et al. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/ refractory B-cell non-Hodgkin lymphoma. *Clin Cancer Res.* 2019;25(23):6986-6994.

149. Kalff A, Khong T, Mithraprabhu S, et al. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). *Leuk Lymphoma.* 2019;60(9):2143-2151.

150. Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. *Oncologist.* 2020;25(5):e808-e815.

151. Karasic TB, Chiorean EG, Sebti SM, O'Dwyer PJ. A phase I study of GGTI-2418 (geranylgeranyl transferase I inhibitor) in patients with advanced solid tumors. *Target Oncol.* 2019;14(5):613-618.

152. Kaufman PA, Wildiers H, Freyer G, et al. Phase 1b study of trebananib plus paclitaxel and trastuzumab in patients with HER2-positive locally recurrent or metastatic breast cancer. *Clin Breast Cancer.* 2019;19(1):47-57.

153. Keilholz U, Mehnert JM, Bauer S, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. *J Immunother Cancer.* 2019;7(1):12.

154. Kelly CM, Shoushtari AN, Qin LX, et al. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. *Invest New Drugs.* 2019;37(2):282-290.

155. Khot A, Brajanovski N, Cameron DP, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. *Cancer Discov.* 2019;9(8):1036-1049.

156. Kim JW, Lee KH, Kim JW, et al. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. *Br J Cancer.* 2019;121(4):332-339.

157. Kim RD, Sarker D, Meyer T, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. *Cancer Discov.* 2019;9(12):1696-1707.

158. Kim SB, Meric-Bernstam F, Kalyan A, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. *Target Oncol.* 2019;14(5):591-601.

159. Kim ST, Lee S, Park M, et al. Combination of docetaxel plus savolitinib in refractory cancer patients: a report on phase I trial. *Transl Oncol.* 2019;12(4):597-601.

160. Kirschbrown WP, Wynne C, Kagedal M, et al. Development of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab: results from the phase Ib dose-finding study. *J Clin Pharmacol.* 2019;59(5):702-716.

161. Knutson KL, Block MS, Norton N, et al. Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine. *Clin Cancer Res.* 2020;26(5):1045-1053.

162. Kobayashi D, Ishigami H, Kanda M, et al. Phase I study of intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. *Oncology.* 2020;98(1):48-52.

163. Kojima Y, Yoshie R, Kawamoto H, et al. Trastuzumab emtansine (T-DM1) plus S-1 in patients with trastuzumab-pretreated HER2-positive advanced or metastatic breast cancer: a phase Ib study. *Oncology.* 2019;96(6):309-317.

164. Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. *Lancet Oncol.* 2019;20(4):570-580.

165. Koyama T, Shimizu T, Iwasa S, et al. First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors. *Cancer Sci.* 2020;111(2):571-579.

166. Kudo T, Takemasa I, Hata T, et al. A phase I study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer. *Oncology.* 2019;97(4):211-216.

167. Kumler I, Eefsen RL, Sorensen PG, et al. An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. *Cancer Chemother Pharmacol.* 2019;84(2):441-446.

168. Kumler I, Sorensen PG, Palshof J, et al. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. *Cancer Chemother Pharmacol.* 2019;83(1):169-178.

169. Kurzrock R, Ball DW, Zahurak ML, et al. A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers. *Clin Cancer Res.* 2019;25(18):5475-5484.

170. Lampert EJ, Hays JL, Kohn EC, et al. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. *Oncotarget.* 2019;10(30):2855-2868.

171. Lapointe S, Mason W, MacNeil M, et al. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00875-4.

172. Lassman AB, Van Den Bent MJ, Gan HK, et al. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: results from an international phase I multicenter trial. *Neuro Oncol.* 2019;21(1):106-114.

173. Leary A, Le Tourneau C, Varga A, et al. Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. *Invest New Drugs.* 2019;37(4):693-701.

174. Lee CK, Scott C, Lindeman GJ, et al. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. *Br J Cancer.* 2019;120(3):279-285.

175. Lee EK, Tan-Wasielewski Z, Matulonis UA, et al. Results of an abbreviated phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. *Gynecol Oncol Rep.* 2019;29:118-122.

176. Lee JH, Chen TW, Hsu CH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. *Invest New Drugs.* 2020;38(1):99‐110.

177. Lee JS, Yost SE, Blanchard S, et al. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. *Breast Cancer Res.* 2019;21(1):119.

178. Lee SJ, Shin SP, Lee SH, et al. Phase I trial of intravenous Ad5CRT in patients with liver metastasis of gastrointestinal cancers. *Cancer Gene Ther.* 2019;26(5-6):174-178.

179. Leighl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. *Lancet Respir Med.* 2019;7(4):347-357.

180. Liem NT, Van Phong N, Kien NT, et al. Phase I clinical trial using autologous ex vivo expanded NK cells and cytotoxic t lymphocytes for cancer treatment in Vietnam. *Int J Mol Sci.* 2019;20(13):3166.

181. Lim B, Murthy RK, Lee J, et al. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. *Br J Cancer.* 2019;120(12):1105-1112.

182. Lin CC, Arkenau HT, Lu S, et al. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. *Br J Cancer.* 2019;121(2):131-138.

183. Lindemann K, Beale PJ, Rossi E, et al. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). *Cancer Chemother Pharmacol.* 2019;83(1):97-105.

184. Liu J, Li X, Zhang H, et al. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial. *Pharmazie.* 2019;74(11):688-693.

185. Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. *Gynecol Oncol.* 2019;154(2):314-322.

186. Lockhart AC, Bauer TM, Aggarwal C, et al. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. *Invest New Drugs.* 2019;37(1):87-97.

187. Lok SW, Whittle JR, Vaillant F, et al. A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2- positive metastatic breast cancer. *Cancer Discov.* 2019;9(3):354-369.

188. Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. *Lancet Gastroenterol Hepatol.* 2019;4(9):711-720.

189. Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood.* 2019;134(21):1811-1820.

190. Luu T, Frankel P, Beumer JH, et al. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. *Cancer Chemother Pharmacol.* 2019;84(6):1201-1208.

191. Lynce F, Wang H, Petricoin EF, et al. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. *Cancer Chemother Pharmacol.* 2019;84(5):1145-1151.

192. Ma S, Suchomel J, Yanez E, et al. Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. *Br J Clin Pharmacol.* 2019;85(8):1751-1760.

193. Ma WW, Xie H, Fetterly G, et al. A phase Ib study of the FGFR/VEGFR inhibitor dovitinib with gemcitabine and capecitabine in advanced solid tumor and pancreatic cancer patients. *Am J Clin Oncol.* 2019;42(2):184-189.

194. MacDonald A, Scarfe G, Magirr D, et al. Phase I study of orally administered (14)carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies. *Cancer Chemother Pharmacol.* 2019;83(4):787-795.

195. Machiels JP, Salazar R, Rottey S, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). *J Immunother Cancer.* 2019;7(1):20.

196. Mahadevan D, Lanasa MC, Farber C, et al. Phase i study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. *J Immunother Cancer.* 2019;7(1):227.

197. Mahalingam D, Wang JS, Hamilton EP, et al. Phase 1 open-label, multicenter study of first-in-class RORgamma agonist LYC-55716 (cintirorgon): safety, tolerability, and preliminary evidence of antitumor activity. *Clin Cancer Res.* 2019;25(12):3508-3516.

198. Mahalingam D, Wilkinson G, Eng KH, et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase 1b study. *Clin Cancer Res.* 2019;26(1):71-81.

199. Mahipal A, Ejadi S, Gnjatic S, et al. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. *Cancer Immunol Immunother.* 2019;68(7):1211-1222.

200. Mahipal A, Tella SH, Kommalapati A, et al. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. *Invest New Drugs.* 2019;37(3):473-481.

201. Mak G, Soria JC, Blagden SP, et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. *Br J Cancer.* 2019;120(10):975-981.

202. Maraka S, Groves MD, Mammoser AG, et al. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. *Cancer.* 2019;125(3):424-433.

203. Marti FEM, Jayson GC, Manoharan P, et al. Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. *Eur J Cancer.* 2019;117:48-59.

204. Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. *Blood.* 2019;133(11):1201-1204.

205. Martin P, Ruan J, Furman R, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. *Leuk Lymphoma.* 2019;60(12):2917-2921.

206. Massard C, Soria JC, Krauss J, et al. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. *Cancer Chemother Pharmacol.* 2019;83(6):1057-1063.

207. McCleary-Wheeler AL, Carr RM, Palmer SR, et al. Phase 1 trial of vismodegib and erlotinib combination in metastatic pancreatic cancer. *Pancreatology.* 2019;21:21.

208. McHugh D, Eisenberger M, Heath EI, et al. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. *Invest New Drugs.* 2019;37(5):1052-1060.

209. Mehnert JM, Kaveney AD, Malhotra J, et al. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2019;84(4):899-907.

210. Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. *BMC Cancer.* 2019;19(1):196.

211. Mettu NB, Niedzwiecki D, Rushing C, et al. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. *Cancer Chemother Pharmacol.* 2019;83(6):1025-1035.

212. Michaelson MD, Gupta S, Agarwal N, et al. A phase Ib study of axitinib in combination with crizotinib in patients with metastatic renal cell cancer or other advanced solid tumors. *Oncologist.* 2019;24(9):1151-e1817.

213. Miller TW, Traphagen NA, Li J, et al. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. *J Neurooncol.* 2019;144(3):563-572.

214. Minami H, Fujiwara Y, Muro K, Sato M, Moriya A. Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers. *Cancer Chemother Pharmacol.* 2019;84(2):337-343.

215. Minev BR, Lander E, Feller JF, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. *J Transl Med.* 2019;17(1):271.

216. Mirza MR, Bergmann TK, Mau-Sorensen M, et al. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. *Cancer Chemother Pharmacol.* 2019;84(4):791-798.

217. Mody K, Mansfield AS, Vemireddy L, Nygren P, Gulbo J, Borad M. A phase I study of the safety and tolerability of VLX600, an iron chelator, in patients with refractory advanced solid tumors. *Invest New Drugs.* 2019;37(4):684-692.

218. Moehler M, Maderer A, Ehrlich A, et al. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. *BMC Cancer.* 2019;19(1):55.

219. Moore KN, Bendell JC, LoRusso PM, et al. First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. *Invest New Drugs.* 2019;37(1):147-158.

220. Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP-54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. *Gynecol Oncol.* 2019;154(2):294-301.

221. Moore KN, Miller A, Bell-McGuinn KM, et al. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. *Gynecol Oncol.* 2020;156(1):13-22.

222. Morgensztern D, Karaseva N, Felip E, et al. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. *Lung Cancer.* 2019;136:74-79.

223. Morikawa A, De Stanchina E, Pentsova E, et al. Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases. *Clin Cancer Res.* 2019;25(13):3784-3792.

224. Mukherjee S, Fountzilas C, Boland PM, et al. Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastric or gastroesophageal junction adenocarcinoma. *Target Oncol.* 2020;15(1):85-92.

225. Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. *Cancer Sci.* 2019;110(5):1686-1694.

226. Naing A, Infante J, Goel S, et al. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. *J Immunother Cancer.* 2019;7(1):225.

227. Naing A, Wong DJ, Infante JR, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. *Lancet Oncol.* 2019;20(11):1544-1555.

228. Nakajima TE, Boku N, Doi A, et al. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. *Invest New Drugs.* 2020;38(2):410-418.

229. Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. *Lancet Haematol.* 2019;6(2):e100-e109.

230. Ng K, Hendifar A, Starodub A, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. *Invest New Drugs.* 2019;37(1):159-165.

231. Nishida S, Tsuboi A, Tanemura A, et al. Immune adjuvant therapy using Bacillus Calmette-Guerin cell wall skeleton (BCG-CWS) in advanced malignancies: a phase 1 study of safety and immunogenicity assessments. *Medicine (Baltimore).* 2019;98(33):e16771.

232. Nishio M, Murakami H, Ohe Y, et al. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. *Invest New Drugs.* 2019;37(6):1207-1217.

233. Nishio M, Takahashi T, Yoshioka H, et al. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. *Cancer Sci.* 2019;110(3):1012-1020.

234. Noel M, O'Reilly EM, Wolpin BM, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. *Invest New Drugs.* 2020;38(3):800-811.

235. Noguchi E, Tamura K, Hattori M, et al. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. *Breast Cancer.* 2019;26(1):39-46.

236. Nokihara H, Nishio M, Yamamoto N, et al. Phase 1 study of cabozantinib in Japanese patients with expansion cohorts in non-small-cell lung cancer. *Clin Lung Cancer.* 2019;20(3):e317-e328.

237. O'Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. *Blood.* 2019;134(17):1395-1405.

238. O'Donnell PH, Arkenau HT, Sridhar SS, et al. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. *Cancer.* 2020;126(2):432-443.

239. O'Dwyer M, Henderson R, Naicker SD, et al. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. *Blood Adv.* 2019;3(12):1815-1825.

240. Oh DY, Lee KW, Han SW, et al. A first-in-human phase I study of GC1118, a novel anti-epidermal growth factor receptor antibody, in patients with advanced solid tumors. *Oncologist.* 2019;24(8):1037-e1636.

241. Ohmachi K, Ogura M, Suehiro Y, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. *Int J Hematol.* 2019;109(6):657-664.

242. Ota D, Akatsuka S, Nishi T, et al. Phase I study of combination therapy with weekly nanoparticle albumin-bound paclitaxel and cyclophosphamide in metastatic breast cancer patients. *Anticancer Res.* 2019;39(12):6903-6907.

243. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. *J Clin Oncol.* 2019;37(4):318-327.

244. Page DB, Pucilowska J, Sanchez KG, et al. A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer. *Clin Cancer Res.* 2019;12:12.

245. Pal SK, Forero-Torres A, Thompson JA, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. *Cancer.* 2019;125(7):1124-1132.

246. Paluri R, Madan A, Li P, et al. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2019;83(3):551-559.

247. Panizza BJ, de Souza P, Cooper A, Roohullah A, Karapetis CS, Lickliter JD. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). *EBioMedicine.* 2019;50:433-441.

248. Park JS, Hong MH, Chun YJ, Kim HR, Cho BC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. *Lung Cancer.* 2019;134:46-51.

249. Petrylak DP, Kantoff P, Vogelzang NJ, et al. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. *Prostate.* 2019;79(6):604-613.

250. Phillips T, Barr PM, Park SI, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. *Invest New Drugs.* 2019;37(2):297-306.

251. Portal DE, Weiss RE, Wojtowicz M, et al. Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. *Cancer Gene Ther.* 2019;doi:10.1038/s41417-019-0112-z.

252. Postel-Vinay S, Herbschleb K, Massard C, et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. *Eur J Cancer.* 2019;109:103-110.

253. Quintela-Fandino M, Apala JV, Malon D, et al. Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. *Breast Cancer Res.* 2019;21(1):69.

254. Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma. *J Immunother Cancer.* 2019;7(1):269.

255. Rasco DW, Papadopoulos KP, Pourdehnad M, et al. A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies. *Clin Cancer Res.* 2019;25(1):90-98.

256. Ravandi F, Koumenis I, Johri A, et al. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. *Haematologica.* 2019;doi:10.3324/haematol.2019.229583.

257. Reiman T, Savage KJ, Crump M, et al. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study+. *Leuk Lymphoma.* 2019;60(4):912-919.

258. Rivkin SE, Moon J, Iriarte DS, et al. Phase Ib with expansion study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. *Int J Gynecol Cancer.* 2019;29(2):325-333.

259. Rizell M, Eilard MS, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma. *Front Oncol.* 2019;9:19.

260. Rolfo C, de Vos-Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. *Clin Pharmacokinet.* 2019;58(9):1165-1174.

261. Rosen LS, Wesolowski R, Baffa R, et al. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. *Invest New Drugs.* 2020;38(1):120-130.

262. Rosenbaum E, Kelly C, D'Angelo SP, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. *Oncologist.* 2019;24(10):1309-e1983.

263. Rosenthal M, Curry R, Reardon DA, et al. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. *Cancer Chemother Pharmacol.* 2019;84(2):327-336.

264. Rovithi M, Gerritse SL, Honeywell RJ, et al. Phase I dose-escalation study of once weekly or once every two weeks administration of high-dose sunitinib in patients with refractory solid tumors. *J Clin Oncol.* 2019;37(5):411-418.

265. Roy DC, Lachance S, Cohen S, et al. Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis. *Br J Haematol.* 2019;186(5):754-766.

266. Ruiz-Borrego M, Jimenez B, Antolin S, et al. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. *Invest New Drugs.* 2019;37(1):98-108.

267. Saif MW, Rajagopal S, Caplain J, et al. A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors. *Cancer Chemother Pharmacol.* 2019;84(6):1323-1331.

268. Saif MW, Rosen L, Rudek MA, et al. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. *Br J Clin Pharmacol.* 2019;85(6):1239-1246.

269. Sandhu S, McNeil CM, LoRusso P, et al. Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. *Invest New Drugs.* 2020;38(3):844-854.

270. Sankhala K, Takimoto CH, Mita AC, et al. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. *Invest New Drugs.* 2019;37(1):76-86.

271. Sato Y, Sagawa T, Ohnuma H, et al. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. *Cancer Chemother Pharmacol.* 2019;83(1):161-167.

272. Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. *Lancet Haematol.* 2019;6(4):e194-e203.

273. Schneeweiss A, Hess D, Joerger M, et al. Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer-lack of association between activating AKT mutation and AKT inhibition-derived efficacy. *Cancers (Basel).* 2019;11(12):10.

274. Schokker S, van der Woude SO, van Kleef JJ, et al. Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel to capecitabine and oxaliplatin (CapOx) as first-line treatment of metastatic esophagogastric adenocarcinoma (ACTION study). *Cancers (Basel).* 2019;11(6):827.

275. Schuler M, Cho BC, Sayehli CM, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol.* 2019;20(10):1454-1466.

276. Schweizer MT, Wang H, Bivalacqua TJ, et al. A phase I study to assess the safety and cancer-homing ability of allogeneic bone marrow-derived mesenchymal stem cells in men with localized prostate cancer. *Stem Cells Transl Med.* 2019;8(5):441-449.

277. Seitz L, Jin L, Leleti M, et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. *Invest New Drugs.* 2019;37(4):711-721.

278. Seront E, Schmitz S, Papier M, et al. Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck. *Front Oncol.* 2019;9:155.

279. Serrano C, Leal A, Kuang Y, et al. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors. *Clin Cancer Res.* 2019;25(24):7287‐7293.

280. Shah CH, Pappot H, Agerbaek M, et al. Safety and activity of sorafenib in addition to vinflunine in post-platinum metastatic urothelial carcinoma (vinsor): phase I trial. *Oncologist.* 2019;24(6):745-e213.

281. Shah HA, Fischer JH, Venepalli NK, et al. Phase I study of aurora a kinase inhibitor alisertib (mln8237) in combination with selective vegfr inhibitor pazopanib for therapy of advanced solid tumors. *Am J Clin Oncol.* 2019;42(5):413-420.

282. Shah J, Usmani S, Stadtmauer EA, et al. Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk.* 2019;19(9):570-578.e571.

283. Shaik N, Hee B, Liang Y, LaBadie RR. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. *Clin Pharmacol Drug Dev.* 2019;8(7):895-902.

284. Shapiro GI, LoRusso P, Kwak E, et al. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. *Invest New Drugs.* 2020;32(2):419-432.

285. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol.* 2019;30(7):1121-1126.

286. Sheng X, Yan X, Chi Z, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial. *J Clin Oncol.* 2019;37(32):2987-2999.

287. Shimizu Y, Yoshikawa T, Kojima T, et al. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. *Cancer Sci.* 2019;110(10):3049-3060.

288. Shimomura A, Yamamoto N, Kondo S, et al. First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in patients with advanced solid tumors. *Mol Cancer Ther.* 2019;18(3):531-540.

289. Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *Lancet Oncol.* 2019;20(6):827-836.

290. Shitara K, Satoh T, Iwasa S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. *J Immunother Cancer.* 2019;7(1):219.

291. Shitara K, Ueha S, Shichino S, et al. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. *J Immunother Cancer.* 2019;7(1):195.

292. Shitara K, Yodo Y, Iino S. A phase I study of napabucasin plus paclitaxel for Japanese patients with advanced/recurrent gastric cancer. *In Vivo.* 2019;33(3):933-937.

293. Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). *Transl Oncol.* 2019;12(6):828-835.

294. Siddiqi T, Frankel P, Beumer JH, et al. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. *Leuk Lymphoma.* 2020;61(2):309‐317.

295. Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. *J Clin Oncol.* 2019;37(12):946-953.

296. Smith DC, Chugh R, Patnaik A, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. *Invest New Drugs.* 2019;37(4):722-730.

297. Somaiah N, Block MS, Kim JW, et al. First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. *Clin Cancer Res.* 2019;25(19):5808-5817.

298. Song A, Andrews DW, Werner-Wasik M, et al. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. *Radiother Oncol.* 2019;132:135-141.

299. Soumerai JD, Davids MS, Werner L, et al. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. *Leuk Lymphoma.* 2019;60(12):2931-2938.

300. Spaner DE, McCaw L, Wang G, Tsui H, Shi Y. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: results of a phase I trial. *Cancer Med.* 2019;8(4):1540-1550.

301. Stega J, Noel MS, Vandell AG, Stega D, Del Priore G, Hoffman S. A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00758-8.

302. Stein MN, Goodin S, Gounder M, et al. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. *Invest New Drugs.* 2020;38(3):855-865.

303. Stein MN, Malhotra J, Tarapore RS, et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. *J Immunother Cancer.* 2019;7(1):136.

304. Stewart AK, Krishnan AY, Singhal S, et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. *Blood Cancer J.* 2019;9(2):17.

305. Strati P, Nastoupil LJ, Davis RE, et al. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. *Haematologica.* 2020;105(1):e26-e28.

306. Strauss J, Heery CR, Kim JW, et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. *Clin Cancer Res.* 2019;25(1):99-109.

307. Strickler JH, Rushing CN, Niedzwiecki D, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. *BMC Cancer.* 2019;19(1):1032.

308. Suenaga M, Wakatsuki T, Mashima T, et al. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00749-9.

309. Sullivan RJ, Hamid O, Gonzalez R, et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. *Nat Med.* 2019;25(6):929-935.

310. Sullivan RJ, Hollebecque A, Flaherty KT, et al. A phase 1 study of LY3009120, a pan-RAF inhibitor, in patients with advanced or metastatic cancer. *Mol Cancer Ther.* 2020;19(2):460-467.

311. Sun Y, Yang L, Hao X, et al. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors. *J Hematol Oncol.* 2019;12(1):9.

312. Suzuki H, Uemura H, Mizokami A, et al. Phase I trial of TAK-385 in hormone treatment-naive Japanese patients with nonmetastatic prostate cancer. *Cancer Medicine.* 2019;8(13):5891-5902.

313. Sweet K, Komrokji RS, Padron E, et al. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. *Clin Cancer Res.* 2020;26(1):54-60.

314. Syrios J, Kouroussis C, Kotsakis A, et al. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. *Minerva Ginecol.* 2019;71(3):182-190.

315. Takahashi S, Uemura M, Kimura T, et al. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00844-x.

316. Takebe N, Beumer JH, Kummar S, et al. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. *Br J Clin Pharmacol.* 2019;85(11):2499-2511.

317. Takeda M, Ohe Y, Horinouchi H, et al. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. *Lung Cancer.* 2019;137:64-70.

318. Takeuchi S, Hase T, Shimizu S, et al. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. *Cancer Sci.* 2019;111(2):561-570.

319. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood.* 2019;134(11):851-859.

320. Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. *Lancet Oncol.* 2019;20(6):816-826.

321. Tanaka J, Tanaka N, Wang YH, et al. Phase I study of cellular therapy using ex vivo expanded NK cell from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients. *Haematologica.* 2020;105(4):e190-e193.

322. Tang B, Yan X, Sheng X, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. *J Hematol Oncol.* 2019;12(1):7.

323. Tao JJ, Cangemi NA, Makker V, et al. First-in-human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. *Clin Cancer Res.* 2019;25(18):5458-5465.

324. Teixeira L, Medioni J, Garibal J, et al. A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors. *Clin Cancer Res.* 2019;doi:10.1158/1078-0432.CCR-19-1614.

325. Teknos TN, Grecula J, Agrawal A, et al. A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. *Invest New Drugs.* 2019;37(4):702-710.

326. Thomas A, Virdee PS, Eatock M, et al. Dual Erb B Inhibition in oesophago-gastric cancer (DEBIOC): a phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. *Eur J Cancer.* 2019;124:131-141.

327. Toyoda M, Watanabe K, Amagasaki T, et al. A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2019;83(2):289-299.

328. Tsuboi A, Hashimoto N, Fujiki F, et al. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. *Cancer Immunol Immunother.* 2019;68(2):331-340.

329. Tsuchiya T, Imanaka K, Iwaki Y, et al. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer. *Int J Clin Oncol.* 2019;24(12):1596-1604.

330. Tuscano JM, Maverakis E, Groshen S, et al. A phase I study of the combination of rituximab and ipilimumab in patients with relapsed/refractory B-cell lymphoma. *Clin Cancer Res.* 2019;25(23):7004-7013.

331. Udagawa H, Akamatsu H, Tanaka K, et al. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. *Lung Cancer.* 2019;135:145-150.

332. Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. *Lancet Gastroenterol Hepatol.* 2019;4(8):611-621.

333. Uldrick TS, Goncalves PH, Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer - a phase 1 study. *JAMA Oncol.* 2019;5(9):1332‐1339.

334. Usuki K, Handa H, Choi I, et al. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. *Int J Hematol.* 2019;110(6):654-664.

335. Vaishampayan U, Schoffski P, Ravaud A, et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: Phase Ib results from the JAVELIN Solid Tumor trial. *J Immunother Cancer.* 2019;7(1):275.

336. Valle SJ, Akhter J, Mekkawy AH, et al. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: a phase I first in man study. *Eur J Surg Oncol.* 2019;doi:10.1016/j.ejso.2019.10.033.

337. van Brummelen EMJ, Levchenko E, Domine M, et al. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. *Invest New Drugs.* 2020;38(2):457-467.

338. van der Noll R, Jager A, Ang JE, et al. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00857-6.

339. van der Noll R, Jager A, Ang JE, et al. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (part 1). *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00856-7.

340. Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. *Gynecol Oncol.* 2019;152(2):243-250.

341. Veitch ZW, Cescon DW, Denny T, et al. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. *Br J Cancer.* 2019;121(4):318-324.

342. Vendrely V, Lemanski C, Gnep K, et al. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: results of a phase I dose-escalation study with panitumumab (FFCD 0904). *Radiother Oncol.* 2019;140:84-89.

343. Venepalli NK, Emmadi R, Danciu OC, et al. Phase i study of IGF-methotrexate conjugate in the treatment of advanced tumors expressing IGF-1R. *Am J Clin Oncol.* 2019;42(11):862-869.

344. Vishwanathan K, So K, Thomas K, Bramley A, English S, Collier J. Absolute bioavailability of osimertinib in healthy adults. *Clin Pharmacol Drug Dev.* 2019;8(2):198-207.

345. von Tresckow B, Sayehli C, Aulitzky WE, et al. Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. *Eur J Haematol.* 2019;102(2):163-173.

346. Voss MH, Hierro C, Heist RS, et al. A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations. *Clin Cancer Res.* 2019;25(9):2699-2707.

347. Vu K, Wu CH, Yang CY, et al. Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-cell lymphoma: results of a phase I dose-escalation study. *Clin Cancer Res.* 2020;26(5):1000-1008.

348. Wakabayashi H, Inaki A, Yoshimura K, et al. A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. *Sci Rep.* 2019;9(1):7625.

349. Wang F, He MM, Wang ZX, et al. Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. *BMC Cancer.* 2019;19(1):460.

350. Wang F, Molina J, Satele D, Yin J, Lim VS, Adjei AA. A phase I study of the vascular endothelial growth factor inhibitor vatalanib in combination with pemetrexed disodium in patients with advanced solid tumors. *Invest New Drugs.* 2019;37(4):658-665.

351. Wang J, Qi L, Liu L, et al. A phase I, randomized, single-dose study evaluating the biosimilarity of TAB008 to bevacizumab in healthy volunteers. *Front Pharmacol.* 2019;10:905.

352. Weed DT, Zilio S, Reis IM, et al. The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase I clinical trial. *Front Immunol.* 2019;10:1206.

353. Weekes C, Lockhart AC, Lee JJ, et al. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. *Int J Cancer.* 2019;145(9):2450-2458.

354. Wesolowski R, Sharma N, Reebel L, et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. *Ther Adv Med Oncol.* 2019;11:1758835919854238.

355. Wieduwilt MJ, Pawlowska N, Thomas S, et al. Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results. *Clin Cancer Res.* 2019;25(16):4917-4923.

356. Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. *Invest New Drugs.* 2019;doi:10.1007/s10637-019-00864-7.

357. Xu J, Jia R, Yue C, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. *Clin Cancer Res.* 2019;25(2):515-523.

358. Yamamoto N, Ryoo BY, Keam B, et al. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. *Invest New Drugs.* 2020;38(2):445-456.

359. Yamazaki K, Doi T, Ikeda M, et al. Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma. *Cancer Chemother Pharmacol.* 2019;84(5):1027-1037.

360. Yan ZX, Li L, Wang W, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin's lymphoma. *Clin Cancer Res.* 2019;25(23):6995-7003.

361. Yang JCH, Gadgeel SM, Sequist LV, et al. Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. *J Thorac Oncol.* 2019;14(3):553-559.

362. Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell-lung cancer and leptomeningeal metastases: the BLOOM study. *J Clin Oncol.* 2019:JCO1900457.

363. Yap TA, Winter JN, Giulino-Roth L, et al. Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. *Clin Cancer Res.* 2019;25(24):7331‐7339.

364. Yoo C, Kang J, Lim HY, et al. Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma. *Cancer Res Treat.* 2019;51(2):510-518.

365. Yu Y, Chung CH, Plotka A, et al. A phase 1mass balance study of (14) C-labeled talazoparib in patients with advanced solid tumors. *J Clin Pharmacol.* 2019;59(9):1195-1203.

366. Yuan P, Shentu J, Xu J, et al. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a phase I study in Chinese patients with advanced solid tumours. *Cancer Chemother Pharmacol.* 2019;83(5):963-974.

367. Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. *Nat Med.* 2019;25(5):759-766.

368. Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. *Blood.* 2019;133(18):1964-1976.

369. Zhang J, Zheng H, Gao Y, et al. Phase I pharmacokinetic study of niraparib in Chinese patients with epithelial ovarian cancer. *Oncologist.* 2020;25(1):19‐e10.

370. Zhang P, Raju J, Ullah MA, et al. Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells. *Clin Cancer Res.* 2019;25(6):1749-1755.

371. Zhang YC, Chen ZH, Zhang XC, et al. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. *EBioMedicine.* 2019;43:180-187.

372. Zhou X, Pusalkar S, Chowdhury SK, et al. Mass balance, routes of excretion, and pharmacokinetics of investigational oral 14 C-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. *Invest New Drugs.* 2019;37(4):666-673.

373. Zimmer AS, Nichols E, Cimino-Mathews A, et al. A phase i study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. *J Immunother Cancer.* 2019;7(1):197.

374. Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L, Alexandrov A. First-in-human phase I study of MBC-11, a novel bone-targeted cytarabine-etidronate conjugate in patients with cancer-induced bone disease. *Oncologist.* 2019;24(3):303-e102.